OptimizeRx Corp

Análisis de la acción OptimizeRx Corp (OPRX)

$7.860

-0.118 (-1.50%)Al cierre

Loading chart…
High
8.030
Open
7.995
VWAP
7.86
Vol
115.54K
Mkt Cap
188.54M
Low
7.700
Amount
908.53K
EV/EBITDA, TTM
38.10

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

AI analysis of OptimizeRx Corp (OPRX)

buy

OptimizeRx Corp (OPRX) appears to be a good buy right now, trading at $7.95 with a forward P/E of 7.97, indicating it may be undervalued compared to its earnings potential. Additionally, the company has shown a significant gross margin improvement, reaching 71.32% in Q2 2026, which supports profitability despite recent revenue challenges. The main risk is the revenue decline of 30% year-over-year reported in Q2 2026, which could impact future performance.

Analyst Ratings (1)

+209.54% upside
Buy
1 Buy
0 Hold
0 Sell
Current: 7.86
Mínimo
17.00
Promedio
24.33
Máximo
32.00

Stifel

2026-08-13

Precio objetivo

$12

Buy

B. Riley

2026-05-13

Precio objetivo

$10

Buy

Lake Street

2026-05-13

Precio objetivo

$11

Buy

Stifel

2026-05-13

Precio objetivo

$14

Buy

Stifel

2026-03-06

Precio objetivo

$17

Buy

Métricas de valoración

The current forward P/E ratio for OptimizeRx Corp (OPRX) is 7.97, compared to its 5-year average forward P/E of 48.32.

Forward P/E

Undervalued
5Y Average P/E
48.32
Current P/E
7.97
Sobrevalorada
84.88
Infravalorada
11.75

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
43.62
Current EV/EBITDA
38.10
Sobrevalorada
90.05
Infravalorada
-2.81

Forward P/S

Fair
5Y Average P/S
4.25
Current P/S
1.40
Sobrevalorada
8.93
Infravalorada
-0.43

Alphio AI Price Scenarios for OPRX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OPRX

$17.89

Precio del escenario

B

Base

Base · 50%OPRX

$16.60

Precio del escenario

B

Bear

Bear · 25%OPRX

$15.41

Precio del escenario

Whales holding OPRX

R

Rice Hall James & Associates, LLC

+ HoldingOPRX

+5.36%

3M Return

Cronología de eventos

2026-08-12 (ET)

17:00:00

OptimizeRx Appoints Andy D'Silva as CFO

16:31:00

OptimizeRx Q2 Revenue at $20.5M, Exceeds Expectations

16:30:00

Company Reiterates FY 2026 Guidance, Expects Revenue of $95M to $100M

2026-07-23 (ET)

08:00:00

OptimizeRx Appoints Sarah Bast as Chief Marketing Officer

2026-05-12 (ET)

16:10:00

OptimizeRx Q1 Revenue $18.94M Exceeds Consensus

Noticias

OPRX FAQ — answered by Alphio AI

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

OptimizeRx Corp (OPRX) appears to be a good buy right now, trading at $7.95 with a forward P/E of 7.97, indicating it may be undervalued compared to its earnings potential. Additionally, the company has shown a significant gross margin improvement, reaching 71.32% in Q2 2026, which supports profitability despite recent revenue challenges. The main risk is the revenue decline of 30% year-over-year reported in Q2 2026, which could impact future performance.

1 analysts cover OPRX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 24.33.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis